Why do some people with Alzheimer's disease die without cognitive impairment?

Since the time of Dr. Alois Alzheimer himself, two proteins (beta-amyloid (Aβ) and tau) have become tantamount to Alzheimer's disease (AD). But a Mayo Clinic study challenges the perception that these are the only important proteins accounting for the clinical features of the devastating disease.

In a large clinico-imaging pathological study, Mayo Clinic researchers demonstrated that a third (TDP-43) plays a major role in AD pathology. In fact, people whose brain was TDP positive were 10 times more likely to be cognitively impaired at death compared to those who didn't have the protein, showing that TDP-43 has the potential to overpower what has been termed resilient brain aging. The study was published in the journal Acta Neuropathologica.

Mayo Clinic researchers studied brains of 342 patients who had died with pathologically confirmed AD and divided them into two groups based on the presence or absence of the protein TDP-43. The protein was found in 195 or 57 percent of the cases.

This video is not supported by your browser at this time.

"We wanted to determine whether the TDP-43 protein has any independent effect on the clinical and neuroimaging features typically ascribed to AD and we found that TDP-43 had a strong effect on cognition, memory loss and medial temporal atrophy in AD," says Mayo Clinic neurologist Keith Josephs, M.D., the study's lead investigator and author. "In the early stages of the disease when AD pathology was less severe, the presence of TDP-43 was strongly associated with  cognitive impairment. Consequently, TDP-43 appears to play an important role in the cognitive and neuroimaging characteristics that have been linked to AD."

The study also found that patients who suffered from greater and medial temporal atrophy at the time of death had greater TDP-43 burden and had the protein in a greater number of brain regions.

"This is why we believe that TDP-43 pathology could help shed light on the phenomenon of resilient cognition in AD and explain why some patients remain clinically normal, while others do not, despite both having similar degrees of AD pathology," says Dr. Josephs.  "Our findings suggest that in order to have AD and be cognitively resilient, TDP-43 must be absent, so it should be considered a potential therapeutic target for the future treatment of AD.

More information: "TDP-43 is a key player in the clinical features associated with Alzheimer's disease," Keith A. Josephs, Jennifer L. Whitwell, Stephen D. Weigand, et al, Acta Neuropathologica March 2014

add to favorites email to friend print save as pdf

Related Stories

OHSU discovery may lead to new treatment for ALS

Jul 18, 2012

Researchers at Oregon Health & Science University School of Dentistry have discovered that TDP-43, a protein strongly linked to ALS (Amyotrophic Lateral Sclerosis) and other neurodegenerative diseases, appears to activate ...

Recommended for you

Researchers identify potential biomarker for AD

20 hours ago

Researchers from Boston University School of Medicine (BUSM) report variants in a new gene, PLXNA4, which may increase the risk of developing Alzheimer's disease (AD). The discovery of this novel genetic association may lead ...

Study links enzyme to Alzheimer's disease

Jul 21, 2014

Unclogging the body's protein disposal system may improve memory in patients with Alzheimer's disease (AD), according to a study from scientists at Kyungpook National University in Korea published in The Jo ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

wealthychef
not rated yet Apr 24, 2014
Correlation is not causation especially when the correlation is not 100% Looking forward to the day when we understand what actually causes the decline so we can treat it.